www.fdanews.com/articles/204355-martin-shkreli-faces-trial-in-mid-december-over-antitrust-lawsuit
![Judge court](https://www.fdanews.com/ext/resources/test/Drug-Images/Court.gif?t=1628628280&width=430)
Martin Shkreli Faces Trial in Mid-December Over Antitrust Lawsuit
September 13, 2021
Martin Shkreli will face trial on Dec. 14 over an antitrust lawsuit filed last year by the Federal Trade Commission and N.Y. Attorney General Letitia James, alleging that the former pharma CEO engaged in an anticompetitive scheme to monopolize the toxoplasmosis drug Daraprim (pyrimethamine).
The suit accuses Shkreli, his former business partner, Kevin Mulleady, and Vyera Pharmaceuticals of hiking the price for the antiparasitic drug and illegally restricting generic competition.
The complaint in the U.S. District Court for the Southern District of New York charges that when Vyrea bought Daraprim in August 2015, it raised the list price by 4,000 percent from $17.50 to $750 per tablet.